Literature DB >> 28966451

Usefulness of radium-223 in patients with bone metastases.

Nishant Gupta1, Arushi Devgan1, Itisha Bansal1, Thomas D Olsavsky1, Shuo Li1, Ahmed Abdelbaki1, Yogesh Kumar1.   

Abstract

Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials.

Entities:  

Year:  2017        PMID： 28966451      PMCID： PMC5595381          DOI： 10.1080/08998280.2017.11930213

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  22 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

Review 2.  Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Authors:  Anil Kapoor; Christopher Wu; Bobby Shayegan; Adrian P Rybak
Journal:  Can Urol Assoc J       Date:  2016-12-12       Impact factor: 1.862

Review 3.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

4.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

Authors:  Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

Review 5.  Prostate cancer.

Authors:  Gerhardt Attard; Chris Parker; Ros A Eeles; Fritz Schröder; Scott A Tomlins; Ian Tannock; Charles G Drake; Johann S de Bono
Journal:  Lancet       Date:  2015-06-11       Impact factor: 79.321

6.  Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease.

Authors:  Oliver Sartor
Journal:  Rev Urol       Date:  2004

7.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

8.  Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

Authors:  Christopher Parker; Lin Zhan; Paul Cislo; Jonathan Reuning-Scherer; Nicholas J Vogelzang; Sten Nilsson; Oliver Sartor; Joe M O'Sullivan; Robert E Coleman
Journal:  Eur J Cancer       Date:  2016-12-06       Impact factor: 9.162

9.  Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.

Authors:  S Nilsson; P Cislo; O Sartor; N J Vogelzang; R E Coleman; J M O'Sullivan; J Reuning-Scherer; M Shan; L Zhan; C Parker
Journal:  Ann Oncol       Date:  2016-02-23       Impact factor: 32.976

Review 10.  Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation.

Authors:  Nghi C Nguyen; Muhammad Shah; Leonard J Appleman; Rahul Parikh; James M Mountz
Journal:  Int J Mol Imaging       Date:  2016-09-27
View more
  2 in total

Review 1.  The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.

Authors:  Holis Abdul Holik; Faisal Maulana Ibrahim; Angela Alysia Elaine; Bernap Dwi Putra; Arifudin Achmad; Achmad Hussein Sundawa Kartamihardja
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

2.  The Potential Use of 11C-Choline Positron Emission Tomography/Computed Tomography to Monitor the Treatment Effects of Radium-223 in a Patient with Prostate Cancer.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Norihiko Kamikonya; Yukako Nakanishi; Yusuke Yamada; Takahiko Hashimoto; Toru Suzuki; Shuken Go; Akihiro Kanematsu; Michio Nojima; Koichiro Yamakado
Journal:  Cureus       Date:  2018-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.